For translational applications, sustained intranasal delivery aligns far closer with canonical, long-term longevity phenotypes Source: Open Access Paper: Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs Institution: University of Washington, Seattle, WA Country: USA Journal: bioRxiv (Preprint) Impact Evaluation: The impact score of this journal is 0 (as a preprint server without a formal Clarivate index)
Good habits include: Your spine benefits from regular exercise and stretching, especially forward, backward and from side to side
Other exclusion criteria were chronic renal replacement therapy (RRT), treatment limitation other than do-not-resuscitate, medical history of vasculitis, moribund (defined as an expected survival duration 30 kg/m 2 ) and non-obesity (BMI 30 kg/m 2 )
Not for medical or veterinary use
CagriSema vs Comparators Feature Receptor targets CagriSema Amylin/calcitonin + GLP-1 Tirzepatide (Zepbound) GIP + GLP-1 Semaglutide alone (Wegovy) GLP-1 Cagrilintide alone Amylin/calcitonin (DACRA) Feature Dosing frequency CagriSema Once weekly Tirzepatide (Zepbound) Once weekly Semaglutide alone (Wegovy) Once weekly Cagrilintide alone Once weekly Feature Maintenance dose CagriSema 2.4 mg + 2.4 mg Tirzepatide (Zepbound) Up to 15 mg Semaglutide alone (Wegovy) 2.4 mg Cagrilintide alone 2.4 mg (in REDEFINE arms) Feature Headline weight loss CagriSema 20.4% at 68 wks (REDEFINE 1, treatment-policy) Tirzepatide (Zepbound) Up to 22.5% at 72 wks (SURMOUNT-1, 15 mg arm) Semaglutide alone (Wegovy) 14.9% at 68 wks (REDEFINE 1 reference arm) Cagrilintide alone 11.5% at 68 wks (REDEFINE 1 reference arm) Feature FDA status (June 2026) CagriSema NDA filed Dec 2025

With its ability to potential promote telomere elongation, slow down the aging process, enhance immune function, restore balance to the endocrine system, and provide neuroprotective effects, this treatment offers a wide range of health benefits